JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY, WAKNAGHAT TEST-2 EXAMINATION-2025

B. Tech.-V Semester (BT)

COURSE CODE (CREDITS): 18B1WBT532 (3)

MAX. MARKS: 25

COURSE NAME: COMPARATIVE AND FUNCTIONAL GENOMICS

COURSE INSTRUCTORS: DR. JATA SHANKAR

MAX. TIME: 1 Hour 30 Min

Note: (a) All questions are compulsory.

(b) The candidate is allowed to make Suitable numeric assumptions wherever required for solving problems

Q. No	Question	CO	Marks
Q1	Explain the principle and steps involved in Pyrosequencing How does it	COII	3.5
	differ from traditional Sanger sequencing, and what are its advantages and		
	limitations?		
Q2	Schematically present a gene structure of a cukaryotic gene with	COI	3.5
	features/signals, including splicing sites?		
Q3	Describe the pharmacodynamics of gentinib. Explain its mechanism of	COII	3.5
	action and how it exerts its therapeutic effects in cancer treatment		
Q4	Explain the pharmacokinetic properties of a drug. Discuss how these	CO II	3.5
	pharmacokinetic properties influence its therapeutic use and the		
	management of dosing in patients		
Q5	Give the estimated gene number and the genome sizes of Homo sapiens,	COI	3.5
	calculate and discuss the importance of gene density and evaluate how it		
	reflects their biglogical complexity		
Q6	Agenetic screening was done on 10,000 patients. A change in a	CO III	3.5
	nitrogenous base (i.e., a single nucleotide change) was observed in 10		
	patients at a specific location in the TP53 gene. Is this change a single-		
	nucleotide polymorphism (SNP) or a point mutation? Explain.		
Q7	Highlight the role of SNPs in tumour suppressor genes, TP53 gene, which	CO III	4
i	encodes the p53 protein, in the development and progression of various		
	types of cancer, covering different geographical locations?		